What Is SS-31 and Why Are People Researching It?
SS-31 is a synthetic tetrapeptide, meaning it is built from four amino acids. Its scientific name is elamipretide, and it was developed by researchers at Cornell University in the early 2000s. The peptide is designed to concentrate inside the inner mitochondrial membrane, where it interacts with cardiolipin, a phospholipid that plays a central role in mitochondrial energy production. The idea behind the research is that stabilizing cardiolipin may help preserve mitochondrial function under conditions of stress or disease.
Interest in SS-31 has grown in part because mitochondrial dysfunction shows up across a wide range of conditions, from heart failure to age-related muscle loss to kidney injury. Researchers have explored it in animal models and, more recently, in human trials. The pharmaceutical company Stealth BioTherapeutics advanced elamipretide into Phase 2 and Phase 3 trials for conditions including Barth syndrome and primary mitochondrial myopathy. Those trials are what give SS-31 a more developed human safety record than most peptides in this research space.
It is worth being clear about terminology. When people online discuss SS-31, they are usually referring to the same molecule as elamipretide, but the versions sold as research chemicals are not the pharmaceutical-grade compound used in clinical trials. The research-chemical form is not FDA approved, and quality control varies significantly between suppliers.
What Do Human Trials Actually Show About Safety?
The most detailed human safety data on elamipretide comes from trials in people with serious mitochondrial diseases. A Phase 2 trial published in the Journal of Inherited Metabolic Disease in 2020 enrolled 36 adults with primary mitochondrial myopathy. Participants received subcutaneous injections over 24 weeks. The most commonly reported adverse events were injection-site reactions, including pain, erythema, and bruising. Systemic adverse events were generally mild to moderate, and no treatment-related serious adverse events were attributed to the drug in that cohort.
A separate open-label extension study in Barth syndrome patients, a rare genetic disorder affecting mitochondrial function, also reported injection-site reactions as the dominant side effect. Fatigue and nausea were noted in some participants. These trials involved small populations with specific diseases, so extrapolating their safety findings to healthy adults using research-grade SS-31 is not straightforward.
A 2020 randomized trial published in JACC: Heart Failure examined elamipretide in patients with heart failure with preserved ejection fraction. That trial found no significant difference in adverse event rates between the treatment and placebo groups over a short follow-up period. The sample size was 71 participants, which is small by drug-approval standards. Short-term tolerability in these trials looks relatively clean, but none of these studies were designed to detect rare adverse events or long-term harms.
Documented Side Effects: What the Data Shows
Across the published human trials, injection-site reactions are the most consistently reported side effect. These include localized pain, redness, swelling, and bruising at the injection site. In the primary mitochondrial myopathy trial, injection-site reactions occurred in the majority of participants receiving active drug. Most were described as mild and did not lead to discontinuation.
Systemic side effects reported across trials include fatigue, nausea, and headache, though these were generally not statistically more common than in placebo groups in the controlled studies. No significant cardiovascular, hepatic, or renal toxicity signals emerged in the published trial data, but again, these were short-duration studies in relatively small populations.
Animal studies have explored higher doses and longer durations. In rodent models, SS-31 has been studied for effects on kidney ischemia-reperfusion injury, cardiac function, and skeletal muscle. Those studies have not flagged obvious organ toxicity at the doses used, but animal-to-human translation is imperfect, and the doses and delivery methods in animal research do not map cleanly onto human use.
Who Should Be Especially Cautious?
Pregnant and breastfeeding people have no safety data to draw on. SS-31 has not been studied in pregnancy, and the potential effects on fetal mitochondrial development are entirely unknown. This is a firm gap, and caution is warranted.
People with known kidney or liver disease should be aware that these organs handle peptide clearance, and altered clearance could affect how a compound behaves in the body. The clinical trials excluded participants with significant organ impairment, so there is no safety data for those populations.
Children and adolescents are another group with essentially no data outside of the Barth syndrome trials, which involved a very specific genetic disease context. People who are already taking medications that affect mitochondrial function, including some antibiotics and statins, are in a category where interactions have simply not been studied. A physician familiar with mitochondrial biology is the right person to consult before any decisions are made.
The source of a research-chemical version of SS-31 also matters from a safety standpoint. Pharmaceutical-grade elamipretide used in clinical trials underwent rigorous purity and sterility testing. Research chemicals sold online carry no such guarantee, and contaminants or incorrect concentrations introduce risks that are entirely separate from the peptide itself.
What Is Still Unknown?
Long-term safety in healthy people is the biggest gap. Every human trial of elamipretide has enrolled people with diagnosed diseases, and most trials ran for 24 to 48 weeks. There is no published data on what happens with extended use in people without underlying mitochondrial disease.
The effects of SS-31 on hormonal systems, immune function, and reproductive health have not been characterized in humans. Some animal studies have looked at oxidative stress markers and inflammatory pathways, but those findings are preclinical and cannot be applied directly to human outcomes.
Interaction data is also sparse. No published studies have examined how SS-31 behaves alongside common medications, supplements, or other peptides. People who research peptide combinations online are working without any clinical guidance on this question.
Finally, the question of what happens if mitochondrial function is artificially supported in healthy tissue over long periods is genuinely open. Mitochondria are dynamic organelles that respond to cellular signals, and the downstream effects of sustained cardiolipin stabilization in non-diseased cells are not well understood. That is not a reason to assume harm, but it is a reason to stay honest about what is not yet known.